Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Germany / NCT05941455
Starting soon Not applicable

A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve

NCT05941455 · tracked via the Priya Life Science Germany tracker
Sponsor
Jilin Venus Haoyue Medtech Limited
Phase
Not applicable
Started
2023-10-31
Last updated
2023-07-12

Condition(s) studied

Aortic Valve DiseaseCardiovascular Diseases

Investigational drug(s) / intervention(s)

Venus-Neo Surgical Aortic Valve

Venus-Neo Surgical Aortic Valve: Implant of a Venus-Neo Surgical Aortic Valve

Study summary

The goal of this clinical trial is to evaluate the safety, effectiveness, and performance of Venus-Neo Surgical Aortic Valve in subjects who are clinically indicated for aortic valve replacement.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years 2. Patients who are clinically indicated for aortic valve replacement 3. Patients who are willing and able to participate in the follow-up requirements, and provide written informed consent Exclusion Criteria: 1. Previous surgical or/and transcatheter cardiac valve replacement at any site 2. Previous open-heart surgical valve repair at any site 3. Any percutaneous cardiovascular intervention (excluding diagnostic percutaneous coronary artery intervention), cardiovascular surgery, carotid surgery within 30 days 4. Untreated mitral, tricuspid, or pulmonary valve diseases requiring procedural intervention 5. Untreated clinically significant coronary artery diseases requiring revascularization 6. Acute myocardial infarct within the previous 30 days 7. Severe right heart dysfunction 8. Active infection requiring antibiotic therapy including infective endocarditis 9. Hypertrophic obstructive cardiomyopathy (HOCM) 10. Severe symptomatic carotid artery stenosis 11. Stroke or TIA within 3 months or Modified Rankin Scale ≥ 4 disability 12. Chronic kidney disease (eGFR\<45 mL/min/1.73m2) or end-stage renal disease requiring chronic dialysis 13. Hematologic disorders: Leukopenia (WBC \< 3000 cell/mL), anemia (Hgb \< 9 g/dL), thrombocytopenia (Plt\< 50,000 cell/mL), or any known blood clotting disorder, deemed clinically significant after consultation with Hematooncology specialists 14. Severe chronic lung disease 15. Previous organ transplant or currently an organ transplant candidate Anatomical 16. LVEF \< 20% 17. Left ventricular end diastolic diameter (LVEDD) \>70mm 18. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation 19. Native aortic valve geometry and size unfavorable for study bioprosthetic valve General 20. Hemodynamics instability requiring inotropic support or intra-aortic balloon pump (IABP) or other hemodynamic support device, or any mechanical heart assistance 21. Urgent, emergency or salvage surgeries 22. Known intolerance for periprocedural/post-procedural anticoagulation or antiplatelet therapy leading to be unable to undergo index procedure per physicians' judgement 23. Life expectancy ≤ 1 year due to non-cardiac reasons 24. Planned relevant concomitant procedure within 30 days post index procedure 25. Current or recent participation (within 6 weeks prior to index procedure) in another drug or device trial 26. Pregnant, breastfeeding or intend to become pregnant within 1 year 27. Currently incarcerated or unable to give voluntary informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Deutsches Herzzentrum Berlin-Charité Berlin Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05941455 on ClinicalTrials.gov ↗ ← All trials in Germany